AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1975483 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in HR greater than or equal to 20 beats/min without beta‐adrenergic blockade
Number of subjects: 9
Study 352372 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg i.v.
Number of subjects: 0
Study 352372 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg i.v.
Number of subjects: 0
Study 352372 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30430984 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward running speech stimulus at 42, 62, and 82 dBA
Number of subjects: 17
Study 30430984 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward running speech stimulus at 42, 62, and 82 dBA
Number of subjects: 17
Study 30430984 — intervention group
Group type: COMPARATOR
Intervention: Baseline VOR gain
Number of subjects: 17
Study 27667263 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention to eat regular meals on days off
Number of subjects: 60
Study 27667263 — intervention group
Group type: COMPARATOR
Intervention: No implementation intention
Number of subjects: 60
Study 26004217 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised training
Number of subjects: 65
Study 26004217 — intervention group
Group type: COMPARATOR
Intervention: Attention-control condition
Number of subjects: 65
Study 23436818 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR Top 5 list items (relating to antinuclear antibodies, Lyme disease, magnetic resonance imaging, bone absorptiometry, and biologic therapy for rheumatoid arthritis)
Number of subjects: 1052
Study 21980765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ) 500 mg tablets twice daily for 6 months
Number of subjects: 13
Study 21980765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19166660 — intervention group
Group type: EXPERIMENTAL
Intervention: Epo-prostenol
Number of subjects: 0
Study 19166660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study 19166660 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics and oxygen supplementation
Number of subjects: 0
Study 17402835 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 1461
Study 17402835 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 1461
Study 15907417 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery
Number of subjects: 28
Study 15907417 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass surgery
Number of subjects: 28
Study 15907417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both off-pump and on-pump surgery
Number of subjects: 28
Study 12473754 — intervention group
Group type: EXPERIMENTAL
Intervention: GV196771
Number of subjects: 63
Study 12473754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9806660 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 18635
Study 7715965 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor program (n = 21)
Number of subjects: 39
Study 7715965 — intervention group
Group type: COMPARATOR
Intervention: Educational non-humorous presentation (n = 18)
Number of subjects: 39
Study 2781492 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive gold 198 (5-7 mCu)
Number of subjects: 50
Study 2781492 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbed dose of ionizing radiation <80 Gy (Group I)
Number of subjects: 50
Study 2781492 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbed dose of ionizing radiation >100 Gy (Group III)
Number of subjects: 50
Study 697431 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 USP units of sodium heparin
Number of subjects: 212
Study 697431 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 212
Study 30658622 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) group 1: 135N peak force, 125ms impulse duration, 920N/s rate of force application
Number of subjects: 81
Study 30658622 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) group 2: 250N peak force, 125ms impulse duration, 1840N/s rate of force application
Number of subjects: 81
Study 30658622 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) group 3: 250N peak force, 250ms impulse duration, 920N/s rate of force application
Number of subjects: 81
Study 30658622 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMT)
Number of subjects: 81
Study 28804980 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 0
Study 28804980 — intervention group
Group type: COMPARATOR
Intervention: Simple clinical feedback and an alcohol information leaflet
Number of subjects: 0
Study 26162785 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion of 0.3 μg/kg/h
Number of subjects: 30
Study 25183442 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ECS (knee length, 30-40 mm Hg graduated pressure)
Number of subjects: 803
Study 25183442 — intervention group
Group type: COMPARATOR
Intervention: Placebo ECS (identical appearance to active ECS, no therapeutic compression)
Number of subjects: 803
Study 22930773 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device
Number of subjects: 20
Study 19836904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led hepatitis health promotion group sessions (n=87)
Number of subjects: 256
Study 19836904 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing delivered in group sessions (MI-group; n=79)
Number of subjects: 256
Study 19836904 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing delivered in one-on-one sessions (MI-single; n=90)
Number of subjects: 256
Study 17645250 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion plus exercise
Number of subjects: 210
Study 17645250 — intervention group
Group type: COMPARATOR
Intervention: Simple filiform needle needling (Control group I)
Number of subjects: 210
Study 17645250 — intervention group
Group type: COMPARATOR
Intervention: Local blocking therapy (Control group II)
Number of subjects: 210
Study 15898130 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 217
Study 15898130 — intervention group
Group type: COMPARATOR
Intervention: Proton-pump inhibitors (PPI)
Number of subjects: 217
Study 11889190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 8
Study 11889190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10(-7) M, 20 min)
Number of subjects: 8
Study 11889190 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT (serotonin)
Number of subjects: 8
Study 11889190 — intervention group
Group type: COMPARATOR
Intervention: GR 113808 (10(-7) M, 150 min)
Number of subjects: 8
Study 10649920 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% aluminum oxide, 1500 ppm sodium monofluorophosphate in a precipitated calcium carbonate (PCC) base
Number of subjects: 94
Study 10649920 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% calcium peroxide (CP), 1500 ppm sodium monofluorophosphate in a PCC base
Number of subjects: 94
Study 10649920 — intervention group
Group type: COMPARATOR
Intervention: Fluoride placebo dentifrice without stain removal ingredients
Number of subjects: 94
Study 7749170 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoban (tropisetron) administered at 0.2 mg/kg (maximum 5 mg daily)
Number of subjects: 131
Study 1980701 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting benzodiazepines (alprazolam)
Number of subjects: 0
Study 1980701 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting benzodiazepines (diazepam)
Number of subjects: 0
Study 353249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic debridement
Number of subjects: 15
Study 353249 — intervention group
Group type: COMPARATOR
Intervention: Hand instrumentation
Number of subjects: 15
Study 30862511 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher health literacy levels (adequate)
Number of subjects: 858
Study 30862511 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall preference for using technology for provider communication
Number of subjects: 858
Study 31358017 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training combined with conventional physical therapy (RAGT+CPT)
Number of subjects: 19
Study 31358017 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT+CPT)
Number of subjects: 19
Study 28686822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 103
Study 26116609 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered cuff tracheal tube (group T)
Number of subjects: 64
Study 26116609 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical cuff tracheal tube (group C)
Number of subjects: 64
Study 26116609 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (T and C)
Number of subjects: 64
Study 23878355 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of toenail selenium
Number of subjects: 898
Study 21448303 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone health plan with 1,000 IUs of vitamin D(3) and 750 mg of plant-sourced calcium for one year
Number of subjects: 176
Study 21448303 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone health plan with differing amounts of vitamin D(3) and other added bone health ingredients
Number of subjects: 176
Study 21448303 — intervention group
Group type: EXPERIMENTAL
Intervention: Most nutritionally comprehensive plan
Number of subjects: 176
Study 21448303 — intervention group
Group type: COMPARATOR
Intervention: Expected change reference groups (non-intervention and previously published studies on non-plant sources of calcium)
Number of subjects: 176
Study 19786441 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP
Number of subjects: 164
Study 19786441 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 164
Study 16719599 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy beliefs
Number of subjects: 349
Study 16719599 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight control behaviors
Number of subjects: 349
Study 15380402 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1600 pulses, 100% of motor threshold, 5 Hz, 8 s)
Number of subjects: 24
Study 15380402 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24
Study 15380402 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 24
Study 11512037 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (60 mg PO)
Number of subjects: 8
Study 11512037 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (0.4 mg, IM)
Number of subjects: 8
Study 9347850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV) at 5 cm H2O
Number of subjects: 15
Study 9347850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV) at 10 cm H2O
Number of subjects: 15
Study 9347850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV) at 15 cm H2O
Number of subjects: 15
Study 9347850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV) at 20 cm H2O
Number of subjects: 15
Study 9347850 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring f/VT
Number of subjects: 15
Study 9347850 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning from the ventilator
Number of subjects: 15
Study 8276058 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg o.d. with warfarin
Number of subjects: 10
Study 8276058 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 10
Study 3524635 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetaphan camsylate
Number of subjects: 12
Study 3524635 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 12
Study 31238954 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARM2 intervention (gender synchronized GE + FP intervention with two male-only sessions and one couple session)
Number of subjects: 1200
Study 31238954 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARM2 intervention (includes female provider-delivered counseling and broader contraceptive options including IUDs)
Number of subjects: 1200
Study 31238954 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys on demographics, GE and FP indicators at baseline, 9-month, and 18-month follow-ups
Number of subjects: 1200
Study 27497762 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160mg/d
Number of subjects: 375
Study 27497762 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide 50mg/d
Number of subjects: 375
Study 25908321 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone tapering strategies
Number of subjects: 516
Study 23514728 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% rapid-acting insulin dose postexercise
Number of subjects: 11
Study 23514728 — intervention group
Group type: COMPARATOR
Intervention: Full rapid-acting insulin dose postexercise
Number of subjects: 11
Study 23514728 — intervention group
Group type: COMPARATOR
Intervention: 75% rapid-acting insulin dose postexercise
Number of subjects: 11
Study 21999663 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (200 mg.day‐1 for 7 days, 100 mg on days 8-9 and 50 mg on day-10) with fludrocortisone (50 μg for 10 days)
Number of subjects: 376
Study 21999663 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 376
Study 21999663 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone with fludrocortisone
Number of subjects: 376
Study 18502257 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (approximately 40% of energy intake) and combined high-intensity resistance and cardiovascular training (HPEx, n = 8)
Number of subjects: 24
Study 18502257 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-protein diet (approximately 25% of energy intake) and combined high-intensity resistance and cardiovascular training (MPEx, n = 8)
Number of subjects: 24
Study 18502257 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet only (HPNx, n = 8)
Number of subjects: 24
Study 16581862 — intervention group
Group type: EXPERIMENTAL
Intervention: STR-CRE (creatine supplementation)
Number of subjects: 32
Study 16581862 — intervention group
Group type: EXPERIMENTAL
Intervention: STR-PRO (protein supplementation)
Number of subjects: 32
Study 16581862 — intervention group
Group type: COMPARATOR
Intervention: STR-CON (placebo)
Number of subjects: 32
Study 15537475 — intervention group
Group type: EXPERIMENTAL
Intervention: moxifloxacin 0.5%
Number of subjects: 30
Study 15537475 — intervention group
Group type: COMPARATOR
Intervention: gatifloxacin 0.3%
Number of subjects: 30
Study 10926942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX) 20 mg/d for 6 weeks
Number of subjects: 31
Study 10926942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9266130 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8395735 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0
Study 8395735 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 3740651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 10
Study 3740651 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (4 mg)
Number of subjects: 10
Study 3740651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30272625 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-set resistance training (SS, n = 21)
Number of subjects: 62
Study 30272625 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-sets resistance training (MS, n = 20)
Number of subjects: 62
Study 30272625 — intervention group
Group type: COMPARATOR
Intervention: Non-training control group (CG, n = 21)
Number of subjects: 62
Study 29615421 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone heart rate-monitoring application (photoplethysmography)
Number of subjects: 438
Study 29615421 — intervention group
Group type: COMPARATOR
Intervention: Modified Allen test
Number of subjects: 438
Study 26000701 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear aligners
Number of subjects: 60
Study 26000701 — intervention group
Group type: COMPARATOR
Intervention: Fixed preadjusted edgewise appliances
Number of subjects: 60
Study 24534410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor to oximeter first (STOF)
Number of subjects: 150
Study 24534410 — intervention group
Group type: COMPARATOR
Intervention: Sensor to infant first (STIF)
Number of subjects: 150
Study 22791099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 310
Study 22791099 — intervention group
Group type: COMPARATOR
Intervention: No application of fibrin sealant (Control)
Number of subjects: 310
Study 20338772 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable polylactic acid positioning screws
Number of subjects: 66
Study 20338772 — intervention group
Group type: COMPARATOR
Intervention: Titanium positioning screws
Number of subjects: 66
Study 18537509 — intervention group
Group type: EXPERIMENTAL
Intervention: Searching
Number of subjects: 0
Study 18537509 — intervention group
Group type: COMPARATOR
Intervention: Surfing
Number of subjects: 0
Study 15673893 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine (2-CP) 30 or 40 mg, with or without fentanyl (10-20 microg)
Number of subjects: 121
Study 15673893 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine (2-CP)
Number of subjects: 121
Study 12006131 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day
Number of subjects: 50
Study 12006131 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg twice daily during the first week of each month
Number of subjects: 50
Study 12006131 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 150 mg once weekly
Number of subjects: 50
Study 11504743 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus chlorambucil
Number of subjects: 554
Study 11504743 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 554
Study 11504743 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 554
Study 9024515 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hospital discharge criteria met (absence of fever for 24 hours, sterile blood cultures for 24 hours, evidence of bone marrow recovery)
Number of subjects: 33
Study 9024515 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hospital discharge (ANC < 500/mm3)
Number of subjects: 33
Study 7862826 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (pre- and post-smoking trials)
Number of subjects: 24
Study 7862826 — intervention group
Group type: EXPERIMENTAL
Intervention: Active coping
Number of subjects: 24
Study 7862826 — intervention group
Group type: COMPARATOR
Intervention: Passive coping
Number of subjects: 24
Study 2890591 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7
Study 2890591 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 7
Study 2890591 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 7
Study 2890591 — intervention group
Group type: EXPERIMENTAL
Intervention: All three beta-blockers
Number of subjects: 7
Study 31167022 — intervention group
Group type: EXPERIMENTAL
Intervention: Families Improving Together (FIT) intervention
Number of subjects: 0
Study 30485923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal and milk (CM)
Number of subjects: 16
Study 30485923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal, milk, fruits and nuts (CMO)
Number of subjects: 16
Study 30485923 — intervention group
Group type: COMPARATOR
Intervention: Glucose drink (Reference)
Number of subjects: 16
Study 27405337 — intervention group
Group type: EXPERIMENTAL
Intervention: α-cyclodextrin (α-CD), 6 grams P.O. a day, for 12-14 weeks
Number of subjects: 75
Study 27405337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 27405337 — intervention group
Group type: EXPERIMENTAL
Intervention: α-cyclodextrin (α-CD)
Number of subjects: 75
Study 24262496 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave lithotripsy at a rate of 80 shock waves per minute (group 1)
Number of subjects: 60
Study 24262496 — intervention group
Group type: COMPARATOR
Intervention: Shock wave lithotripsy at a rate of 120 shock waves per minute (group 2)
Number of subjects: 60
Study 22243980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Restaurant Eating intervention
Number of subjects: 35
Study 20519752 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine
Number of subjects: 300
Study 20519752 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aluminium hydroxide)
Number of subjects: 300
Study 18453859 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine
Number of subjects: 0
Study 15860688 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH); specific concentration not mentioned; effects observed in both pregnant and nonpregnant myometrium.
Number of subjects: 0
Study 15860688 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated myometrial strips); specific details not provided.
Number of subjects: 0
Study 14509102 — intervention group
Group type: EXPERIMENTAL
Intervention: Modem group (Acculink Modem)
Number of subjects: 0
Study 14509102 — intervention group
Group type: COMPARATOR
Intervention: Control group (telephone reporting)
Number of subjects: 0
Study 14509102 — intervention group
Group type: EXPERIMENTAL
Intervention: Modem group
Number of subjects: 0
Study 14509102 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10805057 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered ketoprofen (12.5 mg)
Number of subjects: 180
Study 10805057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 10805057 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (200 mg)
Number of subjects: 180